Amgen's commitment to innovation sets it apart from other Fortune 100 companies. The company has developed over 100 medicines and therapies that have improved the lives of millions of people worldwide.
Amgen's focus on biotechnology has enabled it to create treatments for complex diseases that were previously untreatable. This includes medicines for cancer, kidney disease, and cardiovascular disease.
One of the key factors that has contributed to Amgen's success is its ability to invest in research and development, with over $1.5 billion spent on R&D in 2020 alone. This investment has led to the development of new medicines and therapies that have transformed the lives of patients.
Amgen's commitment to patient access and affordability has also made it a standout among Fortune 100 companies. The company has implemented various programs to reduce the cost of its medicines and make them more accessible to patients in need.
Worth a look: Stock Quote for Amgen
Financial Performance
Amgen's financial performance is a key aspect of its success as a Fortune 100 company. The company's total cash stands at $8.03 billion (mrq), a significant amount that can be used for various business purposes.
Check this out: Abbvie Company Profile
One notable aspect of Amgen's financials is its debt-to-equity ratio, which has reached a high of 756.65% (mrq). This indicates that the company has taken on a substantial amount of debt to finance its operations.
Amgen's revenue has been steadily increasing over the years. In 2025, the company's net sales are projected to reach $34.45 billion, a slight increase from $33.18 billion in 2024. The company's revenue growth is expected to continue, with projected net sales of $31 billion in 2025.
The company's profitability is also impressive, with a profit margin of 18.96% (ttm). This indicates that Amgen is able to maintain a significant portion of its revenue as profit.
Here's a breakdown of Amgen's revenue and net income for 2024 and 2025:
Amgen's net income has also seen a significant increase, from $4.98 billion in 2024 to $6.26 billion in 2025. This is a testament to the company's ability to generate profits and grow its business.
The company's net debt has also been increasing, reaching $43.64 billion in 2025. This indicates that Amgen has taken on a substantial amount of debt to finance its operations and growth.
For your interest: Meyer Brothers Drug Company
Investor Insights
As one of the largest biotechnology companies in the world, Amgen has consistently delivered impressive returns for its investors.
Amgen's market capitalization is over $140 billion, making it one of the largest publicly traded companies in the world.
The company's strong financials are a key driver of its investor appeal.
Amgen's revenue has grown from $13.6 billion in 2010 to over $25 billion in 2020, a staggering 84% increase.
Its robust pipeline of new treatments has contributed significantly to this growth, with several promising candidates in late-stage development.
Amgen's commitment to innovation has enabled it to stay ahead of the competition and capitalize on emerging trends in the biotech industry.
The company's dividend yield is around 1.3%, making it an attractive option for income-seeking investors.
Amgen's stock price has historically been less volatile than many of its peers, providing a relatively stable investment option.
Check this out: Amgen 401k Match
Research and News
Amgen, a Fortune 100 company, has been making headlines in recent weeks with various updates and announcements. Amgen's stock price has been adjusted by several financial institutions, including Citigroup, Wells Fargo, and Goldman Sachs.
Citigroup has adjusted its price target on Amgen to $295 from $310, maintaining a neutral rating. This change reflects a decrease in the company's stock value.
Amgen has also been involved in several clinical trials and collaborations, including a clinical trial collaboration and supply agreement with Asher Bio on etakafusp alfa in combination with bispecific T-cell engager in patients with small cell lung cancer.
Here are some key updates on Amgen's stock price adjustments:
Amgen has also received approval from the FDA for its Lumakras treatment in combination with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer.
Performance and Comparison
In just one day, Amgen's stock performance dipped by -0.96%. This is a relatively small fluctuation, but it's worth keeping an eye on.
Over the past week, Amgen's stock has shown a significant gain of +3.98%. This is a promising trend, and it's likely due to the company's strong fundamentals and innovative pipeline.
The current month has been a particularly good time for Amgen investors, with a +8.56% increase in stock value. This is a clear indication of the company's growth and potential for long-term success.
A +7.73% increase in stock value over the past month is also noteworthy, and it suggests that Amgen's momentum is building.
However, it's worth noting that the company's stock has experienced some volatility in the past few months, with a -10.74% decline over the past three months and a -15.50% decline over the past six months. This is a reminder that the stock market can be unpredictable and that investors should always do their research and consider multiple factors before making a decision.
Here's a snapshot of Amgen's stock performance over different time periods:
If you're interested in comparing Amgen's performance to that of other companies, you can use the "Compare To" feature to analyze similar stocks using key performance metrics.
Industry and Products
Amgen's top product revenues have been steadily increasing from 2022 to 2024, reaching a total of $1 billion in 2024 alone.
One of Amgen's top products, Enbrel, has been generating significant revenue for the company, with a total of $10 billion in revenue from 2011 to 2024.
Here's a breakdown of Amgen's top product revenues from 2022 to 2024:
Amgen's revenue from Enbrel by region has been steadily increasing from 2011 to 2024, with the highest revenue generated in the US.
Other Pharmaceuticals
The "Other Pharmaceuticals" sector has seen some interesting changes in the market. AMGEN INC. has experienced a 2.73% increase in value over the past 5 days.
ELI LILLY AND COMPANY is a notable performer, with a 2.90% increase in value over the same period. Its 1-year change is even more impressive, with a 11.36% increase.
JOHNSON & JOHNSON has seen a 4.13% increase in value over the past 5 days, while ABBVIE INC. has increased by 3.88%.
Here's a breakdown of the 1-year changes for these companies:
The weighted average of the companies in this sector shows a -0.19% change over the past 5 days.
Products and Regions
Let's take a closer look at how Amgen's top products are performing in different regions. Amgen's top product revenues for 2022-2024 are significant, with some products generating hundreds of millions of dollars in revenue.
Amgen's top product revenues for 2022-2024 range from 500 to 1.5 billion U.S. dollars. The company's top products include several biologics that have been successful in treating various diseases.
Here's a breakdown of Amgen's top product revenues for 2022-2024:
Amgen's revenue from Enbrel, a biologic medication, has also been significant, with revenue ranging from 1 to 3 billion U.S. dollars per year. The revenue from Enbrel is generated from various regions, including the U.S. and abroad.
Amgen's revenue from Enbrel by region for 2011-2024 is as follows:
Amgen's revenue in the U.S. and abroad has been steadily increasing over the years, with revenue ranging from 10 to 20 billion U.S. dollars per year. The company's revenue in the U.S. and abroad for 2006-2024 is as follows:
Recognized for Outstanding ESG Performance
Amgen has been recognized for its outstanding Environmental, Social, and Governance (ESG) performance in various rankings.
The company has been named to Newsweek magazine's list of "America's Most Responsible Companies" for the third consecutive year. This is a testament to Amgen's commitment to addressing the challenges facing society.
Amgen's mission is to serve patients and its ESG programs enable it to achieve that mission responsibly. The company's four ESG pillars include commitments to Healthy People, Healthy Society, Healthy Planet, and a Healthy Amgen.
Here are some of the specific ESG goals Amgen has set for itself:
- Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.
- Improve the diversity of its workforce as well as the diversity of patients participating in clinical trials of potential new Amgen medicines.
- Provide employees with enhanced mental health support, including programs focused on communities of color, as well on the pandemic-related challenges facing parents.
- Double its spend with diverse suppliers in the U.S. and triple its spend with Black-owned businesses by 2023.
- Inspire the next generation of innovators through science education programs sponsored by the Amgen Foundation that reached over 24 million students worldwide last year.
- Help those who are unable to afford the medicines they need through the Amgen Safety Net Foundation, which has provided approximately $6 billion of our medicines at no cost over the past five years to qualifying patients in the United States.
Amgen's commitment to ESG has earned it a spot among the 30 companies that comprise the Dow Jones Industrial Average and the Nasdaq-100 index.
Frequently Asked Questions
What rank is Amgen Forbes?
Amgen ranks 58th on Forbes' list of America's Best Large Employers. This ranking is based on employee feedback from over 45,000 Americans working for large companies.
Featured Images: pexels.com
